Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?
| dc.contributor.author | Schneider, Bryan P. | |
| dc.contributor.author | Sledge Jr, George W. | |
| dc.contributor.department | Medicine, School of Medicine | en_US |
| dc.date.accessioned | 2021-01-29T16:13:35Z | |
| dc.date.available | 2021-01-29T16:13:35Z | |
| dc.date.issued | 2009-05-18 | |
| dc.description.abstract | Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these preclinical studies, and should they affect our willingness to explore anti-VEGF therapy in the adjuvant setting? | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.identifier.citation | Schneider, B.P., Sledge, G.W. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?. Breast Cancer Res 11, 303 (2009). https://doi.org/10.1186/bcr2250 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/25074 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | BioMed Central | en_US |
| dc.relation.isversionof | 10.1186/bcr2250 | en_US |
| dc.relation.journal | Breast Cancer Research | en_US |
| dc.rights | Attribution 4.0 International | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.source | Publisher | en_US |
| dc.subject | Bevacizumab | en_US |
| dc.subject | Trastuzumab | en_US |
| dc.subject | Sunitinib | en_US |
| dc.subject | Micrometastatic Disease | en_US |
| dc.title | Anti-VEGF therapy as adjuvant therapy: clouds on the horizon? | en_US |
| dc.type | Article | en_US |